Michael Emmerson Ward

Michael Emmerson Ward

Auto-generated profile, based on publicly available information

Michael Emmerson Ward

National institute of Neurological Disorders and Stroke, NIH, Bethesda, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in Neuron
Verified
Journal Article
Closed access
RTRuilin Tian
Ruilin Tian
MGMariam A. Gachechiladze
Mariam A. Gachechiladze
CLConnor H. Ludwig
Connor H. Ludwig
MLMatthew T. Laurie
Matthew T. Laurie
JHJason Y. Hong
Jason Y. Hong
MKMartin Kampmann
Martin Kampmann

23 February 2022 in Nature
Verified
Journal Article
Open access
PDF file
ABAnna-Leigh Brown
Anna-Leigh Brown
OWOscar G. Wilkins
Oscar G. Wilkins
MKMatthew J. Keuss
Matthew J. Keuss
SHSarah E. Hill
Sarah E. Hill
MZMatteo Zanovello
Matteo Zanovello
PFPietro Fratta
Pietro Fratta
Variants of UNC13A, a critical gene for synapse function, increase the risk of amyotrophic lateral sclerosis and frontotemporal dementia1–3, two related neurodegenerative diseases defined by mislocalization of the RNA-binding protein TDP-434,5. Here we show that TDP-43 depletion induces robust inclusion of a cryptic exon in UNC13A, resulting in nonsense-mediated decay and loss of UNC13A protein. Two common intronic UNC13A polymorphisms strongly associated with amyotrophic lateral sclerosis and frontotemporal dementia risk overlap with TDP-43 binding sites. These polymorphisms potentiate cryptic exon inclusion, both in cultured cells and in brains and spinal cords from patients with these conditions. Our findings, which demonstrate a genetic link between loss of nuclear TDP-43 function and disease, reveal the mechanism by which UNC13A variants exacerbate the effects of decreased TDP-43 function. They further provide a promising therapeutic target for TDP-43 proteinopathies.

1 September 2019 in Cell
Verified
Journal Article
Open access
YLYa-Cheng Liao
Ya-Cheng Liao
MFMichael S. Fernandopulle
Michael S. Fernandopulle
GWGuozhen Wang
Guozhen Wang
HCHeejun Choi
Heejun Choi
LHLing Hao
Ling Hao
MWMichael E. Ward
Michael E. Ward
Long-distance RNA transport enables local protein synthesis at metabolically-active sites distant from the nucleus. This process ensures an appropriate spatial organization of proteins, vital to polarized cells such as neurons. Here, we present a mechanism for RNA transport in which RNA granules "hitchhike" on moving lysosomes. In vitro biophysical modeling, live-cell microscopy, and unbiased proximity labeling proteomics reveal that annexin A11 (ANXA11), an RNA granule-associated phosphoinositide-binding protein, acts as a molecular tether between RNA granules and lysosomes. ANXA11 possesses an N-terminal low complexity domain, facilitating its phase separation into membraneless RNA granules, and a C-terminal membrane binding domain, enabling interactions with lysosomes. RNA granule transport requires ANXA11, and amyotrophic lateral sclerosis (ALS)-associated mutations in ANXA11 impair RNA granule transport by disrupting their interactions with lysosomes. Thus, ANXA11 mediates neuronal RNA transport by tethering RNA granules to actively-transported lysosomes, performing a critical cellular function that is disrupted in ALS.

5 February 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
YSYingxiao Shi
Yingxiao Shi
SLShaoyu Lin
Shaoyu Lin
KSKim Staats
Kim Staats
YLYichen Li
Yichen Li
WCWen-Hsuan Chang
Wen-Hsuan Chang
JIJustin K. Ichida
Justin K. Ichida

18 May 2018 in Current Protocols in Cell Biology
Verified
Journal Article
Open access
PDF file
MFMichael S. Fernandopulle
Michael S. Fernandopulle
RPRyan Prestil
Ryan Prestil
CGChristopher Grunseich
Christopher Grunseich
CWChao Wang
Chao Wang
LGLi Gan
Li Gan
MWMichael E. Ward
Michael E. Ward
Accurate modeling of human neuronal cell biology has been a long‐standing challenge. However, methods to differentiate human induced pluripotent stem cells (iPSCs) to neurons have recently provided experimentally tractable cell models. Numerous methods that use small molecules to direct iPSCs into neuronal lineages have arisen in recent years. Unfortunately, these methods entail numerous challenges, including poor efficiency, variable cell type heterogeneity, and lengthy, expensive differentiation procedures. We recently developed a new method to generate stable transgenic lines of human iPSCs with doxycycline‐inducible transcription factors at safe‐harbor loci. Using a simple two‐step protocol, these lines can be inducibly differentiated into either cortical (i3Neurons) or lower motor neurons (i3LMN) in a rapid, efficient, and scalable manner (Wang et al., 2017). In this manuscript, we describe a set of protocols to assist investigators in the culture and genetic engineering of iPSC lines to enable transcription factor–mediated differentiation of iPSCs into i3Neurons or i3LMNs, and we present neuronal culture conditions for various experimental applications. © 2018 by John Wiley & Sons, Inc.

1 October 2017 in Stem Cell Reports
Verified
Journal Article
Open access
CWChao Wang
Chao Wang
MWMichael E. Ward
Michael E. Ward
RCRobert Chen
Robert Chen
KLKai Liu
Kai Liu
TTTara E. Tracy
Tara E. Tracy
LGLi Gan
Li Gan
Lowering total tau levels is an attractive therapeutic strategy for Alzheimer's disease and other tauopathies. High-throughput screening in neurons derived from human induced pluripotent stem cells (iPSCs) is a powerful tool to identify tau-targeted therapeutics. However, such screens have been hampered by heterogeneous neuronal production, high cost and low yield, and multi-step differentiation procedures. We engineered an isogenic iPSC line that harbors an inducible neurogenin 2 transgene, a transcription factor that rapidly converts iPSCs to neurons, integrated at the AAVS1 locus. Using a simplified two-step protocol, we differentiated these iPSCs into cortical glutamatergic neurons with minimal well-to-well variability. We developed a robust high-content screening assay to identify tau-lowering compounds in LOPAC and identified adrenergic receptors agonists as a class of compounds that reduce endogenous human tau. These techniques enable the use of human neurons for high-throughput screening of drugs to treat neurodegenerative disease.